GlassScriptPhysician profile
Denise Caro
NPI 1134221724
$2,636.85
in general payments reported to CMS, 2019-2025
9 companies · $98.95 in 2025
The $98.95 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $296 · 2021: $256 · 2022: $552 · 2023: $379 · 2024: $186 · 2025: $98.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $663.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $1,165.76 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.93 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $364.99 | 2019-2025 | Synthroid |
| Astrazeneca Pharmaceuticals LP | $242.92 | 2019-2025 | Lokelma |
| Merck Sharp & Dohme LLC | $199.28 | 2019-2023 | Januvia, Steglatro, Steglujan |
| Eli Lilly Export S.A. Puerto Rico Branch | $125.29 | 2019-2024 | Jardiance, Trulicity |
| Abbott Laboratories | $69.66 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $54.48 | 2020 | |
| Novo Nordisk INC | $22.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Caro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.